neupro
| Name |
NEUPRO® (Rotigotine) |
|
NEUPRO® (Rotigotine Transdermal System) is a dopamine agonist that works by helping to restore the balance of dopamine in the brain. NEUPRO® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on-off” fluctuations). |
|
| Description | NEUPRO® is a non-ergolinic dopamine agonist transdermal patch agonist that works by helping to restore the balance of dopamine in the brain |
| Indication | NEUPRO® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on-off” fluctuations). |
| Strengths | Transdermal System: 2 mg, 4 mg, 6 mg and 8 mg rotigotine per 24 hours |
| Regulatory Status |
EMA approved in February 2006 FDA approved in May 2007 Registered in Bahrain, Kuwait, Oman, UAE, Lebanon, Jordan (4 mg/24 h and 6 mg/24 h) and KSA |
| Business Partner | UCB |
